Stock listing
NASDAQ:SLN Silence Therapeutics PLC Stock
Home listing (NASDAQ) of Silence Therapeutics PLC
Follow Silence Therapeutics PLC into a list and get an email when it puts out news.
Share price · NASDAQ:SLN
$19.81 USD -0.01 (-0.1%)
Close on Nov 20, 2026
- Day range
- $19.80 – $19.83 USDNov 20, 2026
- Volume
- 399,148 sharesNov 20, 2026
- Market cap
- $1.23B USDAt the close on Nov 20, 2026 · price × 62.20M shares outstanding
- 52-week range
- $4.19 – $19.87 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $42.19M USDMedian day 958,192 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:SLN · Home | $19.81 USD | -0.01 (-0.1%) | 399,148 | $19.81 | $19.83 | $19.80 | $19.82 | Close on Nov 20, 2026 |
| OTC:SLNCF | $6.527 USD | +0.171 (+2.7%) | 221 | $6.527 | $6.527 | $6.527 | $6.355 | Close on Nov 12, 2026 |
| Frankfurt:XRP2 | €17.90 EUR | 0.00 (0.0%) | — | €17.70 | €17.90 | €17.70 | €17.90 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:SLN · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $19.81 | -0.01 | -0.1% | $19.81 | $19.83 | $19.80 | 399,148 | |
| $19.82 | +0.02 | +0.1% | $19.79 | $19.83 | $19.79 | 1,471,176 | |
| $19.80 | 0.00 | 0.0% | $19.80 | $19.82 | $19.79 | 1,211,323 | |
| $19.80 | -0.03 | -0.2% | $19.80 | $19.83 | $19.80 | 625,258 | |
| $19.83 | +0.03 | +0.2% | $19.78 | $19.86 | $19.76 | 586,511 | |
| $19.80 | +0.03 | +0.2% | $19.76 | $19.82 | $19.76 | 659,203 | |
| $19.77 | -0.02 | -0.1% | $19.80 | $19.81 | $19.77 | 286,296 | |
| $19.79 | +0.04 | +0.2% | $19.73 | $19.80 | $19.72 | 827,879 | |
| $19.75 | +0.02 | +0.1% | $19.72 | $19.76 | $19.70 | 1,377,348 | |
| $19.73 | +0.01 | +0.1% | $19.75 | $19.77 | $19.72 | 958,192 | |
| $19.72 | -0.08 | -0.4% | $19.78 | $19.80 | $19.72 | 1,403,180 | |
| $19.80 | +0.02 | +0.1% | $19.78 | $19.81 | $19.75 | 1,023,282 | |
| $19.78 | +0.02 | +0.1% | $19.78 | $19.80 | $19.78 | 352,414 | |
| $19.76 | +0.01 | +0.1% | $19.75 | $19.80 | $19.75 | 1,186,300 | |
| $19.75 | -0.05 | -0.3% | $19.74 | $19.80 | $19.74 | 621,425 | |
| $19.80 | +0.09 | +0.5% | $19.71 | $19.80 | $19.71 | 1,814,666 | |
| $19.71 | -0.07 | -0.4% | $19.76 | $19.79 | $19.70 | 2,757,825 | |
| $19.78 | 0.00 | 0.0% | $19.78 | $19.80 | $19.71 | 1,488,165 | |
| $19.78 | +0.11 | +0.6% | $19.66 | $19.87 | $19.65 | 4,654,216 | |
| $19.67 | +0.01 | +0.1% | $19.65 | $19.68 | $19.65 | 2,126,200 | |
| $19.66 | -0.01 | -0.1% | $19.69 | $19.69 | $19.63 | 3,078,400 | |
| $19.67 | +0.06 | +0.3% | $19.61 | $19.67 | $19.60 | 2,801,300 | |
| $19.61 | +0.03 | +0.2% | $19.58 | $19.65 | $19.57 | 13,961,900 | |
| $19.58 | +10.90 | +125.6% | $19.59 | $19.61 | $19.56 | 71,909,500 | |
| $8.68 | -0.67 | -7.2% | $9.10 | $9.22 | $8.66 | 1,131,100 | |
| $9.35 | +0.37 | +4.1% | $8.81 | $9.46 | $8.81 | 2,567,500 | |
| $8.98 | +0.11 | +1.2% | $8.91 | $9.27 | $8.85 | 1,233,200 | |
| $8.87 | -0.78 | -8.1% | $9.53 | $9.565 | $8.71 | 1,450,200 | |
| $9.65 | -0.21 | -2.1% | $9.70 | $10.36 | $9.58 | 551,000 | |
| $9.86 | +0.34 | +3.6% | $9.45 | $10.39 | $9.45 | 844,300 | |
| $9.52 | -0.30 | -3.1% | $9.71 | $9.72 | $9.055 | 1,109,600 | |
| $9.82 | -0.01 | -0.1% | $9.77 | $10.14 | $9.60 | 1,319,600 | |
| $9.83 | -0.31 | -3.1% | $10.12 | $10.19 | $9.63 | 1,583,400 | |
| $10.14 | -0.50 | -4.7% | $10.62 | $10.65 | $10.05 | 976,300 | |
| $10.64 | -0.07 | -0.7% | $10.77 | $10.78 | $10.38 | 973,300 | |
| $10.71 | -0.22 | -2.0% | $10.98 | $11.05 | $10.49 | 1,578,900 | |
| $10.93 | +0.13 | +1.2% | $10.85 | $11.30 | $10.65 | 1,356,300 | |
| $10.80 | -0.40 | -3.6% | $11.19 | $11.26 | $10.76 | 884,400 | |
| $11.20 | +0.02 | +0.2% | $11.13 | $11.42 | $11.01 | 710,700 | |
| $11.18 | -0.04 | -0.4% | $11.25 | $11.47 | $11.03 | 953,200 | |
| $11.22 | -0.29 | -2.5% | $11.50 | $11.70 | $11.18 | 691,400 | |
| $11.51 | -0.78 | -6.3% | $12.21 | $12.35 | $11.06 | 877,000 | |
| $12.29 | +0.04 | +0.3% | $12.27 | $12.50 | $12.17 | 382,100 | |
| $12.25 | +0.05 | +0.4% | $12.39 | $12.44 | $12.03 | 665,700 | |
| $12.20 | -0.50 | -3.9% | $12.59 | $12.74 | $12.14 | 1,141,900 | |
| $12.70 | +0.20 | +1.6% | $12.76 | $13.00 | $12.57 | 690,500 | |
| $12.50 | +0.04 | +0.3% | $12.53 | $12.78 | $12.24 | 983,800 | |
| $12.46 | -0.60 | -4.6% | $13.11 | $13.11 | $12.10 | 1,383,400 | |
| $13.06 | +0.04 | +0.3% | $12.95 | $13.28 | $12.72 | 1,095,300 | |
| $13.02 | -0.29 | -2.2% | $13.32 | $13.42 | $12.88 | 685,900 | |
| $13.31 | -0.24 | -1.8% | $13.38 | $13.81 | $13.04 | 682,600 | |
| $13.55 | -0.14 | -1.0% | $13.60 | $14.00 | $13.36 | 645,900 | |
| $13.69 | -0.90 | -6.2% | $14.24 | $14.47 | $13.40 | 1,351,800 | |
| $14.59 | -0.20 | -1.4% | $14.63 | $14.79 | $14.42 | 611,200 | |
| $14.79 | 0.00 | 0.0% | $14.85 | $15.09 | $14.45 | 572,400 | |
| $14.79 | +0.05 | +0.3% | $14.70 | $15.28 | $14.10 | 634,200 | |
| $14.74 | +1.21 | +8.9% | $13.49 | $14.89 | $13.26 | 1,134,900 | |
| $13.53 | +0.11 | +0.8% | $13.39 | $13.65 | $13.09 | 478,200 | |
| $13.42 | -0.03 | -0.2% | $13.46 | $13.69 | $13.18 | 539,700 | |
| $13.45 | -0.08 | -0.6% | $13.47 | $13.69 | $13.36 | 283,600 | |
| $13.53 | -0.14 | -1.0% | $13.68 | $13.68 | $13.36 | 301,700 | |
| $13.67 | +0.38 | +2.9% | $13.31 | $13.99 | $13.31 | 645,000 | |
| $13.29 | +0.02 | +0.2% | $13.37 | $13.59 | $13.05 | 723,700 | |
| $13.27 | +0.10 | +0.8% | $13.17 | $13.48 | $13.13 | 740,600 | |
| $13.17 | -0.44 | -3.2% | $13.50 | $13.57 | $13.01 | 585,200 |
- Ticker
- NASDAQ:SLN
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
Silence Therapeutics Highlights Recent Business Achievements and Reports Third Quarter 2026 Financial Results
Latest deck · Aug 10, 2026
Technical Presentation (August 2026)
Technical · 21 slides
Latest news
Silence Therapeutics Highlights Recent Business Achievements and Reports Third Quarter 2026 Financial Results
Nov 12, 2026
Closed $19.80 (+0.2%) on Nov 12, 2026
Silence Therapeutics Announces Oral Presentation on SANRECO Phase 2 Study of Divesiran in Polycythemia Vera at ASH 2026
Nov 4, 2026
Closed $19.80 (+0.1%) on Nov 4, 2026
Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, Germany
Oct 19, 2026
Closed $19.58 (+125.6%) on Oct 19, 2026
Silence Therapeutics PLC on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 3 in the last 12 months · 3 in all · newest Nov 12, 2026 · oldest 2026
- Calls
- 5 calls with a replay · 5 with a transcript · latest Feb 27, 2025
- Decks
- 40 decks · latest Aug 10, 2026
Where Silence Therapeutics PLC is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:SLN · Home listing · This page | NASDAQ | United States | USD |
| OTC:SLNCF | OTC | United States | USD |
| gettex:XRP2 | gettex | Germany | EUR |
| LS Exchange:A2QB4J | LS Exchange | Germany | EUR |
| Frankfurt:XRP2 | Frankfurt | Germany | EUR |
| Tradegate:XRP2 | Tradegate | Germany | EUR |
| Stuttgart:XRP2 | Stuttgart | Germany | EUR |
| Munich:XRP2 | Munich | Germany | EUR |
| Dusseldorf:XRP2 | Dusseldorf | Germany | EUR |
| Lang & Schwarz:A2QB4J | Lang & Schwarz | Germany | EUR |
| BOATS:SLN | BOATS | United States | USD |
Valuation
EV/sales 2,159× against a median of 15.4×: the highest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $984.6M USD
- P/E
- Loss
- EV/sales
- 2,159×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 5.7×
- Gross margin
- 95.0%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.07
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Silence Therapeutics PLC · NASDAQ:SLN | US$1.23B | US$984.6M | n/a | 2,159× | n/a | 5.7× | n/a | 0.0× | 1.07 |
| Avalyn Pharma Inc. · NASDAQ:AVLN | US$1.26B | US$946.4M | n/a | n/a | n/a | 3.4× | n/a | 0.0× | 0.12 |
| LB Pharmaceuticals Inc · NASDAQ:LBRX | US$1.26B | US$858.7M | n/a | n/a | n/a | 3.0× | n/a | 0.0× | 0.81 |
| MannKind Corporation · NASDAQ:MNKD | US$1.24B | US$1.46B | n/a | 3.5× | 309× | n/a | −18.1% | n/a | 1.06 |
| Novavax, Inc. · NASDAQ:NVAX | US$1.23B | US$902.3M | n/a | 2.2× | n/a | n/a | −18.6% | n/a | 1.98 |
| Ocular Therapeutix, Inc. · NASDAQ:OCUL | US$1.23B | US$774.9M | n/a | 15.4× | n/a | 2.8× | −648.6% | 0.2× | 1.35 |
| Generate Biomedicines, Inc. · NASDAQ:GENB | US$1.22B | US$895.6M | n/a | 28.1× | n/a | 3.2× | −637.0% | 0.2× | 1.90 |
| Taysha Gene Therapies, Inc. · NASDAQ:TSHA | US$1.21B | US$837.4M | n/a | 153× | n/a | 3.4× | n/a | 0.1× | 1.69 |
| Mineralys Therapeutics, Inc. · NASDAQ:MLYS | US$1.21B | US$585.1M | n/a | n/a | n/a | 2.4× | n/a | 0.0× | 1.39 |
| GH Research PLC · NASDAQ:GHRS | US$1.20B | US$841.0M | n/a | n/a | n/a | 3.4× | n/a | 0.0× | 1.28 |
| Vor Biopharma Inc. · NASDAQ:VOR | US$1.18B | US$697.4M | 0.9× | n/a | n/a | n/a | n/a | n/a | 1.25 |
| Median of the others | US$1.23B | US$849.9M | 0.9× | 15.4× | 309× | 3.2× | −327.8% | 0.0× | 1.32 |
Forecasts
1 strong buy · 4 hold · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 19.75 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.37 · 1 analyst
- Revenue, year to Dec 2026
- 314.9K · 7 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Rhonda Hellums | Executive Vice President, Chief Financial Officer |
| Jaimin B. Shah | SVP, General Counsel |
| Steven Romano | Executive Vice President, Chief Research and Development Officer |
| Curtis Rambaran | Chief Medical Officer |
| Iain Ross | Interim Principal Executive Officer |
| Marie Wikström Lindholm | Chief Scientific Officer |
Board
| Director | Role |
|---|---|
| Iain Ross | Interim Principal Executive Officer |
| Dave Lemus | Non-Executive Director |
| James Ede-Golightly | Non-Executive Director |
| Rhonda Hellums | Executive Vice President, Chief Financial Officer |
| Tim McInerney | Non-Executive Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Silence Therapeutics (NASDAQ:SLN) Q4 2024 Earnings Call | Thu, Feb 27, 2025 · 8:00 AM ET | Replay |
| Silence Therapeutics (NASDAQ:SLN) Q4 2023 Earnings Call | Wed, Mar 13, 2024 · 8:00 AM ET | Replay |
| Silence Therapeutics (NASDAQ:SLN) Q4 2022 Earnings Call | Wed, Mar 15, 2023 · 8:00 AM ET | Replay |
| Silence Therapeutics (NASDAQ:SLN) Q4 2021 Earnings Call | Thu, Mar 17, 2022 · 8:00 AM ET | Replay |
| Silence Therapeutics (NASDAQ:SLN) Q2 2021 Earnings Call | Thu, Aug 12, 2021 · 8:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · Before open | +0.1% |
| Q2 2026 | Aug 10, 2026 · Before open | +29.1% |
| Q1 2026 | May 20, 2026 | +12.5% |
| Q4 2025 | Mar 5, 2026 · Before open | −4.8% |
| Q3 2025 | Nov 6, 2025 · Before open | +3.4% |
| Q2 2025 | Aug 7, 2025 · Before open | +1.1% |
| Q1 2025 | May 8, 2025 · Before open | −3.8% |
| Q4 2024 | Feb 27, 2025 | −5.7% |
| Q3 2024 | Nov 14, 2024 · Before open | −8.3% |
| Q2 2024 | Aug 15, 2024 · Before open | +3.1% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 14, 2024 | +7.3% |
| Q4 2023 | Mar 13, 2024 · Before open | −1.1% |
| Q3 2023 | Nov 14, 2023 · Before open | +2.3% |
| Q2 2023 | Aug 16, 2023 · Before open | +6.2% |
| Q1 2023 | May 16, 2023 | −7.2% |
| Q4 2022 | Mar 15, 2023 | −6.9% |
| Q3 2022 | Nov 10, 2022 | +10.7% |
| Q2 2022 | Sep 14, 2022 | −1.7% |
| Q1 2022 | May 16, 2022 | −1.8% |
| Q4 2021 | Mar 17, 2022 | −0.8% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (August 2026) | Technical | 21 slides | Aug 10, 2026 |
| Corporate Update (August 2026) | Corporate update | 21 slides | Aug 10, 2026 |
| Investor Presentation (June 2026) | Investor deck | 38 slides | Jun 23, 2026 |
| Investor Presentation (March 2026) | Investor deck | 41 slides | Mar 5, 2026 |
| FY2024 Earnings Presentation | Earnings | 23 slides | Feb 27, 2025 |
| Investor Presentation (September 2024) | Investor deck | 35 slides | Sep 5, 2024 |
| Investor Presentation (July 2024) | Investor deck | 33 slides | July 2024 |
| Technical Presentation (June 2024) | Technical | 22 slides | Jun 27, 2024 |
| Investor Presentation (January 2023) | Investor deck | 36 slides | January 2023 |
| Investor Presentation (November 2022) | Investor deck | 34 slides | Nov 16, 2022 |
All 40 decks
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 559.0K | 43.3M | 31.6M | 21.7M | 12.4M | 5.48M | 244.0K | 0 | 16.0K | 770.0K |
| Cost of revenue | 215.0K | 11.8M | 12.9M | 13.5M | 7.46M | 3.76M | 9.74M | 7.94M | 8.71M | |
| Gross profit | 344.0K | 31.4M | 18.8M | 8.19M | 4.96M | 1.72M | 244.0K | -9.74M | -7.93M | -7.94M |
| Research and development | 67.8M | 67.9M | 56.9M | 43.5M | 30.8M | 20.2M | 13.3M | 9.74M | 7.94M | 8.71M |
| Selling, general and administrative | 20.0M | 14.0M | 9.64M | 10.8M | 6.46M | 3.96M | ||||
| Operating income | -91.1M | -63.3M | -64.4M | -61.0M | -45.8M | -35.8M | -22.7M | -20.6M | -14.4M | -11.9M |
| Depreciation and amortization | 312.0K | 336.0K | 369.0K | 379.0K | 425.1K | 496.0K | 482.0K | 399.0K | 433.0K | 310.0K |
| EBITDA | -90.8M | -63.0M | -64.0M | -60.7M | -45.4M | -35.4M | -22.3M | -20.2M | -14.0M | -11.6M |
| Interest expense | 8.00K | 16.0K | 33.0K | 45.0K | 15.0K | 1.54M | ||||
| Income before tax | -88.6M | -44.5M | -53.3M | -49.6M | -45.9M | -36.0M | -22.9M | -20.5M | -3.77M | -10.4M |
| Income tax | 11.0K | 845.0K | 956.0K | 688.0K | -6.45M | -3.49M | -3.29M | -2.12M | -2.16M | -1.92M |
| Net income | -88.6M | -45.3M | -54.2M | -50.3M | -39.4M | -32.5M | -19.6M | -18.4M | -1.62M | -8.44M |
| Earnings per share, basic | -0.63 | -0.33 | -0.49 | -0.52 | -1.33 | -1.19 | -0.78 | -0.79 | -0.07 | -0.36 |
| Earnings per share, diluted | -0.63 | -0.33 | -0.49 | -0.52 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 11.3M | 121.3M | 68.8M | 73.5M | 27.4M | 13.5M | 21.5M | 42.7M | 39.0M | |
| Short-term investments | 73.8M | 26.0M | 0 | 10.0M | 20.0M | 5.04M | 319.0K | 3.00K | ||
| Receivables | 0 | 972.0K | 290.0K | 331.0K | 29.3M | 4.00K | 2.45M | 2.00M | 810.0K | |
| Inventory | 1 | 1.49M | -2.45M | -2.48M | -2.99M | |||||
| Current assets | 118.7M | 187.4M | 103.2M | 86.3M | 76.4M | 37.5M | 29.5M | 45.5M | 42.0M | |
| Property, plant and equipment | 1.58M | 1.82M | 1.94M | 1.94M | 1.13M | 611.0K | 921.0K | 1.17M | 1.38M | |
| Goodwill | 10.6M | 9.39M | 9.98M | 9.68M | 7.59M | 8.13M | 7.69M | 8.13M | 8.03M | 7.71M |
| Total assets | 131.4M | 202.6M | 119.4M | 96.2M | 86.0M | 46.1M | 38.9M | 55.0M | 55.8M | |
| Accounts payable | 4.07M | 2.29M | 1.79M | 1.15M | 462.0K | 528.0K | ||||
| Current liabilities | 13.6M | 16.8M | 22.3M | 15.2M | 25.6M | 9.65M | 3.83M | 2.66M | 1.61M | |
| Total debt | 137.0K | 341.0K | 287.0K | |||||||
| Total liabilities | 69.1M | 68.6M | 97.5M | 87.7M | 76.9M | 25.2M | 3.83M | 2.66M | 1.61M | |
| Shareholders' equity | 62.3M | 134.0M | 22.0M | 27.2M | 8.53M | 9.06M | 20.9M | 35.1M | 52.4M | 54.2M |
| Shares outstanding | 141.7M | 141.7M | 118.8M | 107.8M | 29.7M | 27.3M | 25.0M | 23.4M | 23.3M | 23.3M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -62.3M | -67.6M | -49.5M | -57.0M | 9.19M | -10.8M | 1.73M | -16.8M | -9.60M | -10.1M |
| Capital spending | -55.0K | -211.0K | -56.0K | -173.0K | -1.80M | -514.0K | -9.00K | -188.0K | -173.0K | -537.0K |
| Free cash flow | -62.3M | -67.9M | -49.5M | -57.2M | 7.39M | -11.3M | 1.72M | -16.9M | -9.77M | -10.6M |
| Cash from investing | -48.0M | -22.0M | 19.3M | -20.5M | 11.7M | 9.62M | -15.0M | -4.83M | 13.0M | -4.67M |
| Cash from financing | 15.0K | 142.1M | 31.9M | 52.6M | 41.4M | 15.4M | 5.27M | 341.0K | 48.0K | -101.0K |
| Share buybacks | 0 | 0 | -101.0K | |||||||
| Change in cash | -110.2M | 52.5M | 1.77M | -25.0M | 62.2M | 13.9M | -7.98M | -21.3M | 3.73M | -12.9M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 12, 2026 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Nov 12, 2026 | Meeting notice | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 5, 2026 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Oct 19, 2026 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Oct 19, 2026 | Meeting notice | SEC |
| 8-K · Current report | Oct 19, 2026 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 13, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Oct 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 13, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 12, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Aug 12, 2026 | Offer document | SEC |
| S-3MEF | Aug 11, 2026 | Other filings | SEC |
| 424B5 · Prospectus | Aug 10, 2026 | Offer document | SEC |
| 8-K · Current report | Aug 10, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 10, 2026 | Results | SEC |
| 8-K/A · Current report, amended | Jul 16, 2026 | Management or board change | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 8, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 23, 2026 | Current report | SEC |
| 8-K · Current report | Jun 16, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Jun 11, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | May 28, 2026 | Other filings | SEC |
| 424B5 · Prospectus | May 27, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | May 22, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 22, 2026 | Other filings | SEC |
| 8-K · Current report | May 18, 2026 | Material contract | SEC |
| S-3 · Registration statement | May 18, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 29, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 29, 2026 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Mar 5, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 5, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 5, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 9, 2026 | Big-stake notice | SEC |
| UPLOAD · Letter from the SEC | Jan 9, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Dec 31, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 22, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 22, 2025 | Insider trade | SEC |
| 8-K/A · Current report, amended | Dec 22, 2025 | Management or board change | SEC |
| 8-K · Current report | Dec 22, 2025 | Management or board change | SEC |
| UPLOAD · Letter from the SEC | Dec 18, 2025 | Other filings | SEC |
| 8-K · Current report | Dec 15, 2025 | Management or board change | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| 8-K · Current report | Oct 23, 2025 | Current report | SEC |
| 8-K · Current report | Aug 14, 2025 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| 4 · Change in ownership | Aug 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 30, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 27, 2025 | Meeting outcome | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 25, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 20, 2025 | Insider trade | SEC |
| ARS · Annual report to shareholders | May 16, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | May 16, 2025 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 15, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 8, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| 4 · Change in ownership | May 8, 2025 | Insider trade | SEC |
| PRE 14A · Preliminary proxy statement | May 6, 2025 | Meeting notice | SEC |
| 8-K · Current report | May 6, 2025 | Management or board change | SEC |
| 4 · Change in ownership | May 2, 2025 | Insider trade | SEC |
| 10-K/A · Annual report, amended | Apr 30, 2025 | Annual report | SEC |
| 4 · Change in ownership | Apr 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 24, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 1, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 31, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Feb 27, 2025 | Offer document | SEC |
| 10-K · Annual report | Feb 27, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 27, 2025 | Results | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 11, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 2, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 2, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 2, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 2, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 2, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 2, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 2, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 2, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 2, 2025 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 20, 2024 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Dec 9, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 18, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Nov 14, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| F-3ASR | Oct 22, 2024 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Aug 15, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Aug 2, 2024 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Jun 27, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 24, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 20, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | May 17, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | May 16, 2024 | Current report | SEC |
| EFFECT · Notice that a registration is effective | May 15, 2024 | Other filings | SEC |
| 424B3 · Prospectus | May 14, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | May 10, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 10, 2024 | Other filings | SEC |
| DEL AM | May 8, 2024 | Other filings | SEC |
| F-3 · Registration statement | May 7, 2024 | Offer document | SEC |
| 6-K · Report of a foreign issuer | May 1, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | Apr 29, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | Apr 15, 2024 | Current report | SEC |
| SC 13D/A · Big-stake notice, amended | Mar 27, 2024 | Big-stake notice | SEC |
| 20-F · Annual report | Mar 13, 2024 | Annual report | SEC |
| 6-K · Report of a foreign issuer | Mar 13, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | Feb 23, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 12, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2024 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Feb 5, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | Dec 1, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 14, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 1, 2023 | Current report | SEC |
| SC 13G · Big-stake notice | Sep 1, 2023 | Big-stake notice | SEC |
| 6-K/A · Report of a foreign issuer, amended | Aug 29, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 16, 2023 | Current report | SEC |
| SC 13D/A · Big-stake notice, amended | Aug 14, 2023 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Aug 1, 2023 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Jul 11, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jul 3, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | May 16, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | May 4, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | May 1, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Apr 27, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Mar 28, 2023 | Current report | SEC |
| 20-F · Annual report | Mar 15, 2023 | Annual report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 8, 2023 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Jan 12, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 10, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 7, 2022 | Current report | SEC |
| SC 13D/A · Big-stake notice, amended | Oct 20, 2022 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Sep 29, 2022 | Current report | SEC |
| SC 13G · Big-stake notice | Aug 22, 2022 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Aug 19, 2022 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Aug 16, 2022 | Current report | SEC |
| 424B5 · Prospectus | Aug 12, 2022 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Aug 12, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 11, 2022 | Current report | SEC |
| SC 13D/A · Big-stake notice, amended | Jul 20, 2022 | Big-stake notice | SEC |
| SC 13D · Big-stake notice | Jun 15, 2022 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Jun 14, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | May 16, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | May 16, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | Apr 25, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | Apr 4, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | Mar 23, 2022 | Current report | SEC |
| 20-F · Annual report | Mar 17, 2022 | Annual report | SEC |
| 6-K · Report of a foreign issuer | Feb 22, 2022 | Current report | SEC |
| SC 13G · Big-stake notice | Feb 14, 2022 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 14, 2022 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 10, 2022 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Feb 9, 2022 | Current report | SEC |
| SC 13G · Big-stake notice | Feb 7, 2022 | Big-stake notice | SEC |
This page holds 200 of 280 filings. Open Filings
Cap table
Built by 6ix from Silence Therapeutics PLC’s releases
- Common shares
- 62,203,024
- Fully diluted
- 62,203,024
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 62,203,024 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 62,203,024 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Michael Davidson Other companies: BioAge Labs, Inc. (Independent Director · Since at least Mar 26, 2024); NewAmsterdam Pharma Company N.V. (Chief Executive Officer · Since at least Dec 29, 2023); Tenax Therapeutics, Inc. (Board Director · Since at least Feb 25, 2021); Lisata Therapeutics, Inc. (Director · Jul 28, 2020 – Jan 10, 2022 · Past); Omthera Pharmaceuticals Inc (Executive VP & CMO · Apr 11, 2013 – Jul 18, 2013 · Past) | Director · Jan 2, 2025 – Jan 2, 2025 · Past |
| Steven J Romano Other companies: Dianthus Therapeutics, Inc. (Director · Since at least Sep 16, 2024); Mallinckrodt Inc (EVP & Chief Sci. Ofcr · Jun 16, 2022 – Jun 16, 2022 · Past) | EVP and Chief R&D Officer · Since at least Jan 2, 2025 |
| Rhonda Hellums Other companies: Aratana Therapeutics Inc (CHIEF FINANCIAL OFFICER · Feb 1, 2019 – Jul 18, 2019 · Past) | Executive Vice President, Chief Financial Officer · Since at least Jan 2, 2025 |
| Curtis Rambaran | Chief Medical Officer · Since at least Nov 5, 2026 |
| Dave Lemus | Non-Executive Director · Since at least Nov 4, 2026 |
| David Lemus | Director · Since at least Jan 2, 2026 |
| Iain Ross | Interim Principal Executive Officer · Since at least Oct 19, 2026 |
| Jaimin B. Shah | SVP, General Counsel · Since at least Nov 5, 2026 |
| James Ede-Golightly | Non-Executive Director · Since at least Nov 4, 2026 |
| Marie Wikström Lindholm | Chief Scientific Officer · Since at least Nov 5, 2026 |
All 13 people
| Person | Seat |
|---|---|
| Steven Romano | Executive Vice President, Chief Research and Development Officer · Since at least Nov 4, 2026 |
| Tim McInerney | Non-Executive Director · Since at least Nov 4, 2026 |
| Timothy McInerney | Director · Since at least May 5, 2025 |
Log in to ask 6ix AI your own questions about Silence Therapeutics PLC.